SESSION TITLE: Evaluation and Treatment of ILD
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease. The 2011 ATS/ERS/JRS/ALAT guideline did not recommend drug therapy, but Pirfenidone and Nintedanib became “conditional recommendation for use” on the 2015 guideline because these were proved to reduce disease progression in patients with IPF. To assess the other efficacy of Pirfenidone, we examined Japanese patients with IPF.